UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...

Approximately 1 in 10 patients with Ta low-grade NMIBC recurred after 5 years warrant continued surveillance. Nearly 10% of patients initially diagnosed with Ta low-grade nonmuscle-invasive bladder ...

(RTTNews) - UroGen Pharma Ltd. (URGN) said that the U.S. Food and Drug Administration accepted the New Drug Application or NDA for investigational drug UGN-102 (mitomycin) for intravesical solution.

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...

The MarketWatch News Department was not involved in the creation of this content. -- ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by ...

The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...

Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer. This is an ASCO Meeting ...

A diagnosis of adenocarcinoma of the bladder requires careful and specialized care. Because it is rare, it is essential to be treated by a multidisciplinary team, including a urologic oncologist, ...

Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your abdomen that stores ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating ...